Certain Meds Not Cost-Effective for First-Line Therapy of T2DM - HealthDay News

Certain Meds Not Cost-Effective for First-Line Therapy of T2DM - HealthDay News
Compared with metformin, SGLT2 inhibitors, GLP-1 receptor agonists cost more for treatment in drug-naive patients with type 2 diabetes
MONDAY, Oct. 3, 2022 (HealthDay News) -- Sodium-glucose cotransporter-2 (SGTL2) inhibitors and glucagon-like peptide-1 (GLP1) receptor agonists are effective as first-line therapy for patients with t… [+1548 chars] Read More



Related Stories

See All